Abbott Laboratories (ABT) Long-Term Deferred Tax (2009 - 2026)

Abbott Laboratories' Long-Term Deferred Tax history runs 16 years deep, the most recent figure standing at $18.4 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 9.04% year-over-year to $18.4 billion; the TTM figure through Mar 2026 stood at $18.4 billion (up 9.04% YoY), while the FY2025 annual figure was $18.4 billion, up 11.93% from the prior year.
• Long-Term Deferred Tax came in at $18.4 billion for Q1 2026 at Abbott Laboratories, roughly flat from $18.4 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $18.4 billion in Q4 2025 to a low of $5.4 billion in Q2 2022.
• A 5-year average of $10.4 billion and a median of $7.5 billion in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax surged 131.91% in 2024 and rose 9.04% in 2026, its largest moves.
• Abbott Laboratories' Long-Term Deferred Tax stood at $6.0 billion in 2022, then increased by 17.64% to $7.1 billion in 2023, then soared by 131.91% to $16.5 billion in 2024, then grew by 11.93% to $18.4 billion in 2025, then dropped by 0.35% to $18.4 billion in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $18.4 billion, $18.4 billion, and $17.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison